

# Eduardo Vilar Gomez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7868026/eduardo-vilar-gomez-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

2,293  
citations

19  
h-index

47  
g-index

61  
ext. papers

3,261  
ext. citations

5.7  
avg, IF

5.29  
L-index

#	Paper	IF	Citations
53	REPLY. <i>Hepatology</i> , <b>2021</b> , 74, 531-532	11.2	
52	Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 994-1006	0.7	6
51	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
50	High quality diet, physical activity and college education are associated with low risk of NAFLD among the U.S. population. <i>Hepatology</i> , <b>2021</b> ,	11.2	2
49	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. <i>Journal of Clinical Lipidology</i> , <b>2021</b> , 15, 275-291	4.9	4
48	Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status. <i>Liver International</i> , <b>2021</b> , 41, 2703-2711	7.9	1
47	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 136-145.e6 <sup>19</sup>	6.9	19
46	Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1292-1293.e3	6.9	4
45	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 73, 2238-2250	11.2	7
44	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , <b>2021</b> , 5, 786-797	6	3
43	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00400	4.2	1
42	Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
41	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2980-2988.e4	6.9	5
40	Comorbidity Burden May Be Associated with Increased Mortality in Patients with Severe Acute Liver Injury Referred for Liver Transplantation. <i>Annals of Transplantation</i> , <b>2020</b> , 25, e926453	1.4	
39	ADH1B*2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. <i>Gastroenterology</i> , <b>2020</b> , 159, 929-943	13.3	4
38	Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. <i>Drug Safety</i> , <b>2020</b> , 43, 281-290	5.1	1
37	Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 4	3	5

36	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 674-690	3.1	24
35	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1985-1987.e4	13.3	34
34	Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 302	3	1
33	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , <b>2020</b> , 71, 495-509	11.2	71
32	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 216-225.e5	6.9	46
31	Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2305-2314.e12	6.9	16
30	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 317-328	6.1	29
29	Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211811	3.7	10
28	Reply. <i>Hepatology</i> , <b>2019</b> , 70, 752	11.2	
27	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. <i>BMJ Open</i> , <b>2019</b> , 9, e023597	3	25
26	Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. AuthorsTreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 836-837	6.1	
25	Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. AuthorsTreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 838-839	6.1	
24	Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. <i>Hepatology Communications</i> , <b>2019</b> , 3, 52-62	6	14
23	Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1705-1710	4	5
22	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 328-349	0.9	30
21	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 305-315	13.4	241
20	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 328-349	0.1	1
19	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , <b>2018</b> , 155, 443-457.e173	13.3	308

18	Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. <i>Liver International</i> , <b>2017</b> , 37, 1887-1896	7.9	37
17	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 332-344	6.1	32
16	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 31421	4.9	22
15	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 283-90	3.3	25
14	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , <b>2016</b> , 63, 1875-87	11.2	41
13	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 2266-2267	11.2	
12	Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?. <i>Annals of Internal Medicine</i> , <b>2016</b> , 165, 373-4	8	2
11	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , <b>2015</b> , 149, 367-78.e5; quiz e14-5	13.3	1010
10	Reply: To PMID 25865049. <i>Gastroenterology</i> , <b>2015</b> , 149, 1988-9	13.3	2
9	Oxidative Stress in Autoimmune Liver Disease. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , <b>2015</b> , 325-343		1
8	Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e95736	3.7	4
7	The natural history of compensated HCV-related cirrhosis: a prospective long-term study. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 434-44	13.4	59
6	Trends in digestive cancer mortality, Cuba 1987-2008. <i>European Journal of Public Health</i> , <b>2013</b> , 23, 164-70.1	7.1	2
5	Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. <i>BMJ Open</i> , <b>2011</b> , 1, e000140	3	9
4	Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2638-47	5.6	29
3	Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 999-1009	6.1	73
2	Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2768-77	5.6	9
1	Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. <i>Liver International</i> , <b>2007</b> , 27, 247-59	7.9	11

